This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Free CME: Audio Summary

Advances in Diagnosis of Alzheimer Disease and Emerging Treatment Targets

Danielle Goldfarb, MDa

Published: May 11, 2021

Until recently, the diagnosis of Alzheimer disease (AD) could not be truly made until an autopsy was done. Patients’ diagnosis relied on clinicians’ skills to recognize signs and symptoms of AD, and the diagnosis was often incorrect. The rate of misdiagnosis was higher in earlier disease stages when symptoms are milder. Researchers have made great strides over the past 2 decades in identifying diagnostic biomarkers and treatment targets. Can AD now be diagnosed before patients show symptoms? What do potential treatments look like? This CME presentation highlights exciting developments.

See the entire activity

To cite: Goldfarb D. Advances in diagnosis of Alzheimer disease and emerging treatment targets. J Clin Psychiatry. 2021;82(3):LI19012AS1C.
To share:

© Copyright 2021 Physicians Postgraduate Press, Inc.

aBanner Sun Health Research Institute, Sun City, and University of Arizona College of Medicine, Tucson

Volume: 82

Quick Links: Dementia , Diagnostic Tools , Neurologic and Neurocognitive


Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...